Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 35
Solid patent protection of innovative drugs
Novo Nordisk's position is protected
by patents and value chain setup
EU patent protection¹ US patent protection¹
Barriers to entry for biosimilar players
Research & Development
·
Need to show comparability in PK/PD trials
•
Strict regulatory requirements in EU and the US
•
Requirement for both drug and device offering
Manufacturing
Economies of scale for incumbents
Up-front CAPEX requirements with slow return on investment
OZEMPIC
semaglutide injection
Fiasp
fast-acting insulin aspart
Xultophy
insulin degudec/laglutide
DNA originjection
TRESIBA
insulindegudec DNA origin injection
RYZODEG
70%sindedecand 30spart
DNA anjinjection
VICTOZA
Levemir®
2031
20322
2030
2030
20293
20293
2028
2029
2028
2029
•
20235
20235
2018
2019
(insulin detemir)
NovoMix
Expired4
Expired5
(biphasic insulin aspart)
Novo Rapid
Expired5
Expired5
(insulin aspart)
norditropin
Expired5
Expired5
1 List does not include all marketed products. 2 Assuming paediatric extension. 3 Protected by patents on
the individual compounds insulin degludec and liraglutide as listed. 4 Expired in 2015. 5 Expired in 2017.
Note: Saxenda patent identical to the VictozaⓇ patent.
changing
diabetes®
Commercialisation
Large and fragmented target audience
•
Cost pressure from payers
•
On-going conversion to next generation drugs and slow market
dynamics
PK: Pharmacokinetic, PD: Pharmacodynamic; CAPEX: Capital expenditure
novo nordiskView entire presentation